Cantius Therapeutics

Cantius Therapeutics, LLC has a unique and well-placed strategy to treat cachexia and block nausea/emesis. Our GRASP technology utilizes small peptides that penetrate the brainstem to antagonize the GFRAL-Ret receptor complex. This receptor complex, expressed exclusively in the brainstem, was recently established as the sole mediator of GDF15 (MIC-1) signaling, a cytokine critical in disease-induced cachexia, anorexia, and emetic behaviors from cancer, chemotherapy, and pregnancy-induced morning sickness.

Startup Details

Looking for: Partnerships, Seed Investment, Management

Contact: Neal Lemon.

Reference Docket # 19-8758



Skip to content